Advances in Alzheimer’s disease clinical trials are accelerating rapidly, leading to new insights and disease-modifying therapies, but how does the field continue bolstering that momentum? For Dr. Rema Raman, it’s through improving inclusivity and training for early-career researchers. Recorded at the 2024 Alzheimer’s Disease & Related Dementias Research Day, Dr. Raman joins the podcast to discuss her work in research recruitment and retention, the importance of training the next generation of clinical trialists in dementia research with the IMPACT-AD program and more from her featured presentation.
Guest: Rema Raman, PhD, co-director, Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), director, section of biostatistics, section of participant recruitment & retention section, Alzheimer’s Therapeutic Research Institute, professor of neurology, University of Southern California
Show NotesWatch our YouTube page for upcoming recordings of Dr. Raman’s presentation and other featured speakers at Alzheimer’s Disease & Related Dementias Research Day 2024.
Learn more about Alzheimer’s Disease & Related Dementias Research Day on our website.
Learn more about the Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) on their website.
Learn more about Dr. Raman at her bio on the Keck School of Medicine website.
Connect with usFind transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
Agitation and Alzheimer’s: Strategies for Managing Behavioral and Psychological Symptoms of Dementia
Promises to Practice: Creating Sustainable Community Partnerships to Support Alzheimer’s Research
Study Shows APOE Gene Affects Hispanic Populations’ Risk of Cognitive Decline Differently to Non-Hispanic Populations
Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment
Deciding to Donate: Barriers and Benefits of Brain Donations for Diverse Populations
Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness
Understanding the Social Determinants of Health and Disparities in Alzheimer’s Research
Take Care of Your MIND: Reviewing the MIND Diet for Healthy Brain Aging
The National Strategy for Diversifying Alzheimer’s Research
The Future of Neuroscience: Early-Career Researchers Named ’One to Watch’ by the Alzheimer’s Association
Studies Look at Generational Differences and Associations between Cognition, Sensory Changes and Blood Biomarkers
Disclosing Alzheimer’s Disease Biomarker Results in Diverse Populations
Difficult but Beneficial Conversations about End-of-Life Care
Caregiving While Black: Dementia Care for Different Racial and Ethnic Groups
Our Evolving Understanding of Mild Cognitive Impairment
A Closer Look at the Lecanemab Clinical Trials
Therapeutic Fibbing: Mastering the Art of Communicating with a Loved One with Dementia
The Future of the Alzheimer’s Association: Interview with Dr. Joanne Pike and Harry Johns
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
Healthy Habits for the New Year and Modifiable Risk Factors for Alzheimer’s Disease
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks